<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01147666</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-040</org_study_id>
    <nct_id>NCT01147666</nct_id>
  </id_info>
  <brief_title>Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of FG-4592 in maintaining
      and/or correcting hemoglobin (Hb) given to subjects with End Stage Renal Disease(ESRD)on
      maintenance hemodialysis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose ranging study with consecutive cohorts in two subject populations: patients normally
      responding to current anemia treatment (epoetin alfa) (&quot;normoresponders&quot;) and patients not
      responding well to current treatment (&quot;hyporesponders&quot;). Normoresponders are randomized to
      study drug FG-4592 or epoetin alfa; hyporesponders are randomized to study drug FG-4592 or
      epoetin alfa or placebo. The study objectives are to demonstrate that FG-4592 is effective in
      maintaining hemoglobin (Hb) levels when converting from epoetin alfa and to establish optimum
      starting doses and dose adjustment regimens for Hb maintenance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin maintenance using various FG-4592 dosing regimens</measure>
    <time_frame>week 6 and 17-20</time_frame>
    <description>Outcome measure 1: Number (%) of subjects with hemoglobin levels at Week 6 within -0.5 g/dL from baseline
Outcome measure 2: Number (%) of subjects with hemoglobin greater than or equal to 11 g/dL at Weeks 17, 18, 19 and 20</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate dose adjustments to maintain hemoglobin in ESRD patients</measure>
    <time_frame>6 weeks; 19 weeks</time_frame>
    <description>Outcome measure: Number of dose adjustments required during the dosing period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate pharmacokinetic and pharmacodynamic parameters</measure>
    <time_frame>19 weeks</time_frame>
    <description>Outcome measure 1: trough plasma FG-4592 concentration at week 1, 4 and 6 in all subjects
Outcome measure 2: plasma FG-4592 concentration and EPO concentration at various hours after dosing in a subset of subjects</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Population A; Experimental Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients responding normally to current treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population A; Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients responding normally to current treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population B; Experimental Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients not responding well to current treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population B; Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients not responding well to current treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population B; Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients not responding well to current treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>Different dose levels</description>
    <arm_group_label>Population A; Experimental Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <description>Per current label instruction</description>
    <arm_group_label>Population A; Active Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>Different dose levels</description>
    <arm_group_label>Population B; Experimental Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive capsules matching appearance of FG-4592 capsules</description>
    <arm_group_label>Population B; Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <description>Per current label instruction</description>
    <arm_group_label>Population B; Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age 18 to 75 years

          2. End-stage renal disease (ESRD) and receiving maintenance hemodialysis

          3. Two most recent hemoglobin values obtained during screening period must be within the
             ranges set below:

               -  Croup A. Normoresponder Criteria: Hb range in the 8 weeks prior to randomization
                  within 9.0 to 13.5 g/dL

               -  Group B. Hyporesponder Criteria: Hb range in the 8 weeks prior to randomization
                  within 8.5 to 13.5 g/dL

          4. Epoetin alfa, dose requirements:

               -  Group A. Normoresponder Criteria - Cohorts A-1 to A-12: Stable IV epoetin alfa
                  dose at baseline (i.e., no more than a 30% fluctuation in the weekly dose) during
                  the 4 weeks prior to study Day -3

                    -  Cohorts A-1 to A-4: Current and previous (past 4 weeks) epoetin alfa dose
                       range 25 to 85 IU/kg/dose, three times a week (TIW); weekly dose between 75
                       and 255 IU/kg/week

                    -  Cohort A-5: Current and previous (past 4 weeks) epoetin alfa dose range
                       =/&gt;85 to 115 IU/kg/dose, TIW; total weekly dose between 255 and 335
                       IU/kg/week

                    -  Cohort A-9: Current and previous (past 4 weeks) epoetin alfa dose range
                       =/&gt;85 to 150 IU/kg/dose, TIW; total weekly dose between 255 and 450
                       IU/kg/week

                    -  Cohorts A-6 to A-8: Current and previous (past 4 weeks) epoetin alfa dose
                       range 25 to 115 IU/kg/dose, TIW, and two times a week (BIW); total weekly
                       dose between 75 and 345 IU/kg/week

                    -  Cohorts A-10 to A-12: Optional cohorts TBD, dosing frequency and dose range
                       to be determined by sponsor

               -  Group B. Hyporesponder Criteria:

                    -  Cohort B-1 (completed): Current and previous (past 4 weeks) epoetin alfa
                       dose range 125 to 400 IU/kg/dose, TIW; weekly dose between 375 and 1200
                       IU/kg/week

                    -  Cohort B-2 to B-4: Current and previous (past 4 weeks) epoetin alfa dose
                       range &gt;115 IU/kg/dose, TIW; total weekly dose &gt;345 IU/kg/week no requirement
                       for stability of epoetin alfa doses

          5. Complete Blood Count (CBC), Hematology, liver function blood tests, serum folate and
             vitamin B12 within acceptable limits

          6. Absence of active or chronic gastrointestinal bleeding

          7. hsCRP &lt;60 mg/L for normoresponders Cohorts A-8 through A-12 enrolled under Amendment
             3; no hsCRP criteria for hyporesponders

          8. Body weight: 40 to 140 kg (dry weight)

          9. Body mass index (BMI): 18 to 45 kg/m2

         10. Dialysis vascular access via native arteriovenous fistula or synthetic graft, or
             permanent (tunneled) catheter (not via temporary catheter); permanent and temporary
             catheters, however, are still prohibited in Cohort A-5

        Key Exclusion Criteria:

          1. Anticipated change in hemodialysis prescription

          2. Any clinically significant infection or evidence of an underlying infection

          3. Positive for any of the following: Human immunodeficiency virus (HIV); hepatitis B
             surface antigen (HBsAg); or anti-hepatitis C virus antibody (anti-HCV Ab)

          4. History of chronic liver disease

          5. New York Heart Association Class III or IV congestive heart failure

          6. Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus
             erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in
             remission

          7. History of myelodysplastic syndrome

          8. History of hemosiderosis, hemochromatosis, polycystic kidney disease, or anephric

          9. Active hemolysis or diagnosis of hemolytic syndrome

         10. Known bone marrow fibrosis

         11. Uncontrolled or symptomatic secondary hyperparathyroidism

         12. Any prior organ transplantation

         13. Drug-treated gastroparesis or short-bowel syndrome

         14. History of alcohol or drug abuse; or a positive drug screen for a substance that has
             not been prescribed for the subject

         15. Prior treatment with FG-4592

         16. Diagnosis or suspicion of renal cell carcinoma

         17. RBC transfusion within 12 weeks prior to Day 1, or anticipated need for RBC
             transfusion during the dosing period

         18. IV iron supplement within 2 weeks prior to Day 1 and/or unwilling to withhold IV iron
             during the dosing/Treatment period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marietta Franco</last_name>
    <role>Study Director</role>
    <affiliation>FibroGen</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pine Bluff</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yuba City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosedale</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>June 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>ESRD</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>CKD</keyword>
  <keyword>Renal</keyword>
  <keyword>Anemia</keyword>
  <keyword>Oral anemia treatment</keyword>
  <keyword>Hemoglobin levels</keyword>
  <keyword>Blood count</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Normoresponder</keyword>
  <keyword>Hyporesponder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

